title: The HCV NS5B nucleoside and non-nucleoside inhibitors.
abstract: This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.
authors.affiliation: Alamo Medical Research, San Antonio, TX 78215, USA.
authors.forename: Fernando E
authors.initials: FE
authors.lastname: Membreno
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Lawitz
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006157:Guanosine Monophosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000627:therapeutic use; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D003841:Deoxycytidine; D006157:Guanosine Monophosphate; D000069474:Sofosbuvir; D014542:Uridine Monophosphate; D017361:Viral Nonstructural Proteins; C552098:2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine; C557801:IDX184; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase